Futibatinib – November 2025

• Brand names:
  • Lytgobi®
• Pharmaceutical Company:
  • TAIHO PHARMA OCEANIA PTY LTD
• Condition/Indication: Bile duct cancer (cholangiocarcinoma)
• Meeting Date: November 2025
• Public Summary Document (PSD) July 2025 November 2025 PBAC Meetings - (PDF 581KB)
• Public Summary Document (PSD) July 2025 November 2025 PBAC Meetings - (Word 146KB)

Related Public Summary Documents

• Futibatinb – July 2025